Advances in research of miRNA regulated tumor-associated gene c-met

Abstract

Abstract:

C-met is the member of the tyrosine kinase receptor (receptor tyrosinekinases, RTKs) family. It can change different signal pathways in cell after combination with its ligand hepatocyte growth factor (HGF). The microRNA (miRNA) is a kind of highly conservative, endogenous, non-coding single small RNA whose length is about 19-25 nucleotides. It regulates gene expression after transcription by affecting the stability of the target mRNA or inhibit its translation. It plays an important role in many biological processes in the biological process. Studies have shown that miRNAs can regulate the expression of c-met, inhibit tumor cell proliferation, migration and invasion. Regarding the miRNA related to tumor gene c-met regulation research progress are summarized.

Key words: receptor tyrosinekinases, c-met, miRNA, tumor

CLC Number:

R966
R73

MEI Ying, LIU Chaoqi. Advances in research of miRNA regulated tumor-associated gene c-met[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 204-209.

References

［1］Hanna JA, Bordeaux J, Rimm DL, et al. The function, proteolytic processing, and histopathology of Met in cancer［J］. Adv Cancer Res, 2009, 103: 1-23.
［2］Loyer X, Mallat Z, Boulanger CM, et al. MicroRNAs as therapeutic targets in atherosclerosis［J］. Expert Opin Ther Targets, 2015, 19(4): 489-496.
［3］Peng J, Qi S, Wang P, et al. Diagnosis and prognostic significance of c-met in cervical cancer: a meta-analysis［J］. Dis Markers, 2016, 2016: 6594016.
［4］Sun C, Liu Z, Li S, et al. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colonyformation［J］. Oncotarget, 2015, 6(28): 25533-25574.
［5］Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology［J］. Cancer Treat Rev, 2013, 39(7): 793-801.
［6］Gately K, Forde L, Cuffe S, et al. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer［J］. Clin Lung Cancer, 2014, 15(1): 58-66.
［7］Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance［J］. Pharmacol Ther, 2014, 142(3): 316-338.
［8］Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer［J］. J Clin Oncol, 2013, 31(8): 1089-1096.
［9］Cipriani NA, Abidoye OO, Vokes E, et al. MET as a target for treatment of chest tumors［J］. Lung Cancer, 2009, 63(2): 169-179.
［10］Taulli R, Bersani F, Foglizzo V, et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation［J］. J Clin Invest, 2009, 119(8): 2366-2378.
［11］Kefas B, Godlewski J, Comeau L, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma［J］. Cancer Res, 2008, 68(10): 3566-3572.
［12］Li Y, Vandenboom TG II, Wang Z, et al. miR-146a suppresses invasion of pancreatic cancer cells［J］. Cancer Res, 2010, 70(4): 1486-1495.
［13］Mataki H, Seki N, Chiyomaru T, et al. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma［J］. Int J Oncol, 2015, 46(3): 1039-1050.
［14］Zheng Z, Yan D, Chen X, et al. MicroRNA-206: effective inhibition of gastric cancer progression through the c-met pathway［J］. PLoS One. 2015, 10(7): e0128751.
［15］Luan S, Sun L, Huang F. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251［J］. Arch Med Res, 2010, 41(2): 67-74.
［16］Guessous F, Zhang Y, Kofman A, et al. MicroRNA-34a is tumor suppressive in brain tumors and glioma stem cells［J］. Cell Cycle, 2010, 9(6): 1031-1036.
［17］Zauli G, Voltan R, di Iasio MG, et al. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells［J］. Clin Cancer Res, 2011, 17(9): 2712-2724.
［18］Siemens H, Jackstadt R, Hünten S, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions［J］. Cell Cycle, 2011, 10(24): 4256-4271.
［19］Liu YW, Sun M, Xia R, et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer［J］. Cell Death Dis, 2015, 6: e1802.
［20］Wang Y, Shi J, Chai K, et al. The role of snail in EMT and tumorigenesis［J］. Curr Cancer Drug Targets, 2013, 13(9): 963-972.
［21］Liu WT, Jing YY, Yu GF, et al. Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53［J］. Cell Cycle, 2016, 15(7): 886-894.
［22］Hong JH, Roh KS, Suh SS, et al. The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients［J］. Tumour Biol, 2015, 36(12): 9327-9337.
［23］Li C, Wang Y, Lu S, et al. MiR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor α［J］. Mol Med Rep, 2015, 12(5): 7072-7078.
［24］Sanchez I, Dynlacht BD. Cell biology: short RNAs and shortness of breath［J］. Nature, 2014, 510(7503): 40-42.
［25］Sun L, Bian G, Meng Z, et al. MiR-144 inhibits uveal melanoma cell proliferation and invasion by regulating c-met expression［J］. PLoS One, 2015, 10(5): e0124428.
［26］Zhang LY, Ho-Fun Lee V, Wong AM, et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN［J］. Carcinogenesis, 2013, 34(2): 454-463.
［27］Alam R, Schultz CR, Golembieski WA, et al. PTEN suppresses SPARC-induced pMAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma［J］. Neuro Oncol, 2013, 15(4): 451-461.
［28］Lan F, Yu H, Hu M, et al. miR-144-3P exerts anti-tumor effects in glioblastoma by targeting c-met［J］. J Neurochem, 2015, 135(2): 274-286.
［29］Yang YM, Lee CG1, Koo JH, et al. Ga12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4a inactivation, which causes c-Met induction［J］. Oncotarget, 2015, 6(22): 19055-19069.
［30］Li ZY, Xi Y, Zhu WN, et al. Positive regulation of hepatic miR-122 expression by HNF4α［J］. J Hepatol, 2011, 55(3): 602-611.
［31］Liu X, Jiang L, Wang A, et al. MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines［J］. Cancer Lett, 2009, 286(2): 217-222.
［32］Yeh YM, Chuang CM, Chao KC, et al. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting sOX4 and HIF-1α［J］. Int J Cancer, 2013, 133(4): 867-878.
［33］Seike M, Goto A, Okano T, et al. MiR-21 is an eGFR-regulated anti-apoptotic factor in lung cancer in never-smokers［J］. Proc Natl Acad Sci U S A, 2009, 106(29): 12085-12090.
［34］Li B, Yang XX, Wang D, et al. MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met［J］. Eur Rev Med Pharmacol Sci, 2016, 20(6): 1109-1114.
［35］Zhuang HQ, Bo QF, Yuan ZY, et al. The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MeT-PI3K-AKT signal transduction［J］. Onco Targets Ther, 2013, 6: 603-608.
［36］Liu Y, Yang Y, Ye YC, et al. Activation of eRK-p53 and eRK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor sU11274 in human lung cancer A549 cells［J］. J Pharmacol Sci, 2012,118(4): 423-432.
［37］Shang N, Arteaga M, Zaidi A, et al. FAK is required for c-Met/beta-catenin-driven hepatocarcinogenesis［J］. Hepatology, 2015, 61(1): 214-226.
［38］Zhen Q, Liu J, Gao L, et al. MicroRNA-200a targets EGFR and c-met to inhibit migration, invasion, and gefitinib resistance in non-small cell lung cancer［J］. Cytogenet Genome Res, 2015, 146(1): 1-8.
［39］Ohta K, Hoshino H, Wang J, et al. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A［J］. Oncotarget, 2015, 6(5): 3211-3224.
［40］Huang J, Dong B, Zhang J, et al. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma［J］. Tumour Biol, 2014, 35(6): 5833-5843.
［41］Kinose Y, Sawada K, Nakamura K, et al. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma［J］. Oncotarget, 2015, 6(13): 11342-11356.
［42］Wu J, Ji A, Wang X, et al. MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells［J］. J Transl Med, 2015, 13(1): 1-15.
［43］Gao Y, Zeng F, Wu JY, et al. MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met［J］. Tumour Biol, 2015, 36(4): 2875-2883.
［44］Wan L, Zhu L, Xu J, et al. MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met［J］. Cell Physiol Biochem, 2014, 34(4): 1273-1290.
［45］Niu G, Li B, Sun J, et al. miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met［J］. Cell Prolif, 2015, 48(3): 348-355.
［46］Zhang Y, Wang Z, Chen M, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer［J］. Mol Cancer, 2012, 11(1): 1-9.
［47］Huang N, Wu Z, Lin L, et al. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling［J］. Oncotarget, 2015, 6(17): 15222-15234.
［48］Dong N, Tang X, Xu B. miRNA-181a inhibits the proliferation, migration, and epithelial-mesenchymal transition of lens epithelial cells［J］. Invest Ophthalmol Vis Sci, 2015, 56(2): 993-1001.
［49］Xu J, Huang Z, Lin L, et al. miR-210 over-expression enhances mesenchymal stem cell survival in an oxidative stress environment through antioxidation and c-Met pathway activation［J］. Sci China Life Sci, 2014, 57(10): 989-997.

[1]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[2]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[3]	WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454.
[4]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[5]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[6]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[7]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[8]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[9]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[10]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[11]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[12]	HONG Ziqiang, GOU Wenxi, CUI Baiqiang, BAI Xiangdou, JIN Dacheng, GOU Yunjiu. Role of the m7G methyltransferase METTL1 in tumours [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 93-100.
[13]	MA A'xue, LU Xiaohong, DONG Bo, WANG Dong. Research progress of exosomal miRNA in skin wound healing and regeneration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 919-924.
[14]	WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin. Research progress on the antitumor effect of nifurtimox [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960.
[15]	WU Shuai, YANG Jun, ZHENG Yun. Dual role of miRNA in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 814-821.